Brain Metastases from Uterine Cervical and Endometrial Cancer

Kato, Mayumi Kobayashi; Tanase, Yasuhito; Uno, Masaya; Ishikawa, Masatoshi; Kato, Tomoyasu

doi:10.3390/cancers13030519

Cited by 17 publications

(16 citation statements)

References 166 publications

(704 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Local disease control has been more successful in the combined approach but OS outcomes were not better [28][29][30]. As a result, there is no consensus on the most effective treatment and patient-tailored therapy seems to be the most logical approach [31]. In this cohort, SRS was used alone or in combination in approximately 25% of patients.…”

Section: Discussionmentioning

confidence: 92%

The clinical outcomes of ovarian cancer in patients with brain metastasis

2021

EJGO

View full text Add to dashboard Cite

To present the clinical characteristics and treatment outcomes of patients with ovarian cancer with brain metastasis. Methods: This study was designed as a retrospective observational study. Patients' data were obtained from hospital records. Patients who were diagnosed with brain metastatic ovarian cancer in two tertiary referral centers between 2012 and 2020 were included in the study. Results: In total, there were 56 patients diagnosed as having brain metastatic ovarian cancer. The median age was 56 years, 91% of patients were at an advanced stage at initial diagnosis. The median time from the initial diagnosis to brain metastasis was 34.0 months. Sixty-seven percent of patients were determined as having multiple brain metastatic lesions. Whole brain radiotherapy (WBRT) , stereotactic radiosurgery (SRS) and combined approach were utilized as primary treatment. The 1 and 2-year survival rates were 38% and 17%, respectively. Patient age and tumor histology were found to be significant prognostic factors that impact the survival in univariate analyses. The 1-year survival of patients aged younger than 55 years was 49.2%, and 28.2% for patients aged over 55 years (p = 0.04). Patients with nonserous histology had significantly longer one year overall survival compared to serous histology (61.4% vs 29.8%) (p = 0.01). Conclusion: The brain is one of the rarest locations for ovarian cancer metastasis. Radiotherapeutic approaches are the mainstay of treatment but survival rates are low. Age and tumor histology were determined as significant parameters that affected survival rates.

show abstract

Section: Discussionmentioning

confidence: 92%

The clinical outcomes of ovarian cancer in patients with brain metastasis

2021

EJGO

View full text Add to dashboard Cite

show abstract

“…A study done by Piura and Piura suggested that out of all gynaecological cancers, the incidence of brain metastasis of ovarian malignancy is 1.2% which is twice the incidence associated with cervical or endometrial cancer. 3 The most common histologic subtype of ovarian carcinoma associated with brain metastasis is the serous type, followed by mixed epithelial, endometrioid adenocarcinoma, mucinous, undifferentiated, and clear cell type. Some studies have demonstrated the correlation between germline mutations of BReast CAncer gene 1 (BRCA-1) mutations and incidence of brain metastases in ovarian carcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…4 In the brain, the cerebrum is the most common site for metastases, followed by the cerebellum, and leptomeninges. 3 The frontal lobe is the most commonly involved area. 4 Symptoms of brain metastases include headaches, nausea, vomiting, confusion, dizziness, decreased mental status, general or extremity weakness, urinary incontinence, gait disturbance, ataxia, visual disturbance including diplopia, photophobia, speech impairment, syncope, and seizures.…”

Section: Discussionmentioning

confidence: 99%

“…In the case of multiple metastases, multimodality treatment approach is advised. 3 The reported median time from primary diagnosis to development of cerebral lesions ranged from 11 to 46 months and directly correlated with the initial tumour grade and stage. 1,4 Patients with poorly differentiated ovarian carcinoma (grade 3) had a median time interval of 1.5 years between diagnosis and brain metastasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Brain Metastasis of Papillary Ovarian Adenocarcinoma

Chhabra¹,

Dalal²,

Singh³

2022

PJP

View full text Add to dashboard Cite

Brain metastasis from epithelial ovarian cancer is a rare diagnostic entity with a reported incidence of 1-2%. Serous epithelial ovarian cancer is usually associated with a poor prognosis and is the most common malignancy metastasizing to the brain. The median time from primary diagnosis to development of cerebral lesions is directly correlated with the initial tumour grade and stage. The median survival after diagnosis of brain metastases is 6 months. It is suggested that brain imaging studies should be included in the follow up of patients after treatment for ovarian carcinoma. We report a case of brain metastasis of ovarian adenocarcinoma 2 years post-surgery and six cycles of chemotherapy.

show abstract

“…It was reported by a recent study that patients with cervical cancer, poorly differentiated carcinoma and early stage disease lead to brain metastases; among patients with endometrial cancer, high grade carcinoma and advanced stage disease are high risk for brain metastases [ 25 ]. In our study, most patients of uterine cancer developed distant metastases were those with undifferentiated tumor group; there were no significant differences in differentiation grade among the cervical cancer or ovarian cancer patients developing distant metastases.…”

Section: Discussionmentioning

confidence: 99%

The risk of distant metastases in patients with gynecologic cancers after surgery: a population-based study

Hsiao

Chen

Hsin

et al. 2021

Aging

View full text Add to dashboard Cite

The aim of the study was to determine the risk of distant metastases in patients with gynecologic cancers after surgery, including cervical, uterine and ovarian cancers. This is a retrospective study evaluating gynecologic cancer from 2009 to 2014 using population-based administrative datasets from the Health and Welfare Data Science Center (HWDC) and from The National Health Informatics Project (NHIP). A total of 1,464 gynecologic cancer patients, including 321 cervical cancer patients, 724 uterine cancer patients and 419 ovarian cancer patients, were analyzed retrospectively from 2009 to 2014. Among the cervical cancer patients, 173 (53.89%) received surgery only and 148 (46.11%) received surgery with radiotherapy /chemotherapy. Among the uterus cancer patients, 425(58.70%) received surgery only and 299 (41.3%) received surgery with radiotherapy /chemotherapy. Among the ovarian cancer patients, 81 (19.33%) received surgery only and 338 (80.67%) received surgery with radiotherapy/chemotherapy. Among patients with brain, liver or lung metastasis, cervical cancer patients have more cumulative metastasis-free survival than those ovarian cancer (p=0.0041). In analyzing liver metastasis based on primary cancer sites, cervical cancer patients and uterine cancer cases have more cumulative metastasis- free survival than those ovarian cancer (p<0.0001). In conclusion, ovarian cancer patients have higher risk of liver metastasis than cervical or uterine cancer. There were significantly different of pathological stage for cumulative metastasis-free survival among gynecologic cancer patients with brain or liver or lung metastasis. Pathological T stage remains the main predictive for distant metastasis of gynecologic cancer.

show abstract

Brain Metastases from Uterine Cervical and Endometrial Cancer

Cited by 17 publications

References 166 publications

The clinical outcomes of ovarian cancer in patients with brain metastasis

The clinical outcomes of ovarian cancer in patients with brain metastasis

Brain Metastasis of Papillary Ovarian Adenocarcinoma

The risk of distant metastases in patients with gynecologic cancers after surgery: a population-based study

Contact Info

Product

Resources

About